Evaluation of an Automated Screening Assay, Compared to Indirect Immunofluorescence, an Extractable Nuclear Antigen Assay, and a Line Immunoassay in a Large Cohort of Asian Patients with Antinuclear Antibody-Associated Rheumatoid Diseases: A Multicenter Retrospective Study

Figure 1

Diagnostic performance of the CTD screen, tested independently and in combination with autoantibody assays. (a) Receiver operating characteristic (ROC) curves of the CTD screen (0.89) and its combination with autoantibody assays for discriminating total antinuclear antibody-associated rheumatoid disease patients () from control subjects (); (b) ROC curves for the CTD screen (0.93) and its combination with autoantibody assays, differentiating patients with systemic lupus erythematosus (SLE) () from control subjects; (c) ROC curves for the CTD screen (0.73) combined with autoantibody assays, differentiating patients with systemic sclerosis (SSc) () from control subjects; (d) ROC curves for the CTD screen (0.93) and its combination with autoantibody assays, discriminating patients with Sjögren’s syndrome (SS) () from control subjects; (e) ROC curves for the CTD screen (0.95) and its combination with autoantibody assays, differentiating patients with mixed connective tissue disease (MCTD) () from control subjects.

(a)

(b)

(c)

(d)

(e)